Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 696 results

Media Release / Jun 07, 2017

Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL

-- At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff-- Best ORR was 59%, with 43…
Media Release / Jun 07, 2017

Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
Media Release / May 08, 2017

Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer

Physicians now have the option of prescribing Kisqali and Femara together in one convenient co-pack Co-Pack allows patients ability to obtain Kisqali and Femara with a single co-pay Approval comes…
Media Release / May 08, 2017

Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
Media Release / Apr 27, 2017

Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada

Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the U.S.; Novartis to gain exclusive rights in CanadaNovartis retains commercial rights in rest of world; Amgen retains commercial rights…
Media Release / Apr 27, 2017

Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada
Media Release / Apr 18, 2017

Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL

-- Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)-- R/r DLBCL, an…
Media Release / Apr 18, 2017

Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Media Release / Mar 29, 2017

Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review

Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cellsNovartis made an early commitment to the…
Media Release / Mar 29, 2017

Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review

‹ Previous page
1
…
38
39
40
41
42
43
44
…
70
› Next page